Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class? Authors’ reply
Linked Content This article is linked to Bonovas et al and Tsai papers. To view these articles visit https://doi.org/10.1111/apt.14449 and https://doi.org/10.1111/apt.14480.
Saved in:
Published in: | Alimentary pharmacology & therapeutics Vol. 47; no. 4; pp. 540 - 541 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Wiley Subscription Services, Inc
01-02-2018
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Linked Content
This article is linked to Bonovas et al and Tsai papers. To view these articles visit https://doi.org/10.1111/apt.14449 and https://doi.org/10.1111/apt.14480. |
---|---|
Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Editorial-2 ObjectType-Commentary-1 |
ISSN: | 0269-2813 1365-2036 |
DOI: | 10.1111/apt.14486 |